| Identification | Back Directory | [Name]
SB-332235 | [CAS]
276702-15-9 | [Synonyms]
SB-332235
1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea
(6-Chloro-3-[3-(2,3-dichlorophenyl)ureido]-2-hydroxybenzenesulfonamide)
SB-332235 (6-Chloro-3-[3-(2,3-dichlorophenyl)ureido]-2-hydroxybenzenesulfonamide)
6-Chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxybenzenesulfonamide
Benzenesulfonamide, 6-chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxy- | [Molecular Formula]
C13H10Cl3N3O4S | [MDL Number]
MFCD20270939 | [MOL File]
276702-15-9.mol | [Molecular Weight]
410.66 |
| Chemical Properties | Back Directory | [Melting point ]
>213°C (dec.) | [storage temp. ]
Refrigerator, under inert atmosphere | [solubility ]
DMSO (Slightly) | [form ]
Solid | [color ]
Pale Brown |
| Hazard Information | Back Directory | [Uses]
SB 332235 is a potent and selective CXCR2 antagonist. In vitro, SB 332235 inhibits proliferation of AML cell lines. | [in vivo]
SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees[1].
SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis[1]. | Animal Model: | Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)[1] | | Dosage: | 10, 25 mg/kg | | Administration: | P.o.; twice a day for 14 days | | Result: | Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.
|
| [storage]
Store at RT |
|
|